Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION After an FAERS cluster in a demographic the trials under-enrolled, scientific-advice briefing book is what pharmacovigilance medical reviewer can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this FDA Response and Labeling file.

DECISION Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend Proceed under protocol from scientific-advice briefing book after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend Proceed under protocol from scientific-advice briefing book; Pause the pathway is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled. 3. An FAERS cluster in a demographic the trials under-enrolled never reached the population in scientific-advice briefing book — reopen intake, do not close to drop a secondary. 4. Two facts in scientific-advice briefing book after an FAERS cluster in a demographic the trials under-enrolled conflict for pharmacovigilance medical reviewer; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after an FAERS cluster in a demographic the trials under-enrolled. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in scientific-advice briefing book, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Owner and next date for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal - What changes to drop a secondary if an FAERS cluster in a demographic the trials under-enrolled is later withdrawn